PFS Partners’s Royalty Pharma RPRX Stock Holding History

PFS Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-206	Closed	-$5.8K	–	487
2023 Q4	$5.8K	Buy	206 +1	+0.5%	+$27	﹤0.01%	328
2023 Q3	$5.56K	Buy	205 +2	+1%	+$59	﹤0.01%	317
2023 Q2	$6.25K	Buy	203 +1	+0.5%	+$34	0.01%	309
2023 Q1	$7.28K	Buy	202 +1	+0.5%	+$37	0.01%	246
2022 Q4	$7.94K	Buy	201 +1	+0.5%	+$42	0.01%	226
2022 Q3	$8.04K	Buy	+200	New	+$8.54K	0.01%	216

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PFS Partners's RPRX Position: Q1 2024 in Review

PFS Partners sold out of Royalty Pharma (RPRX) in Q1 2024, closing a stake of 206 shares — an estimated $5.8K sold.

PFS Partners first reported a position in RPRX in Q3 2022 and held it in 6 quarters. The position peaked at $8.04K in Q3 2022. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

PFS Partners reported no remaining Royalty Pharma position as of Q1 2024 after selling out during the quarter.
PFS Partners sold 206 Royalty Pharma shares in Q1 2024, an estimated $5.8K.
PFS Partners first reported a position in Royalty Pharma in Q3 2022 and held it in 6 quarters.
PFS Partners's Royalty Pharma position peaked at $8.04K in Q3 2022.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on PFS Partners's 13F filing for Q1 2024, filed 15 Apr 2024.